Day One Biopharmaceuticals Inc (DAWN)
16.18
+0.14
(+0.90%)
USD |
NASDAQ |
May 17, 16:00
16.18
0.00 (0.00%)
After-Hours: 20:00
Day One Biopharmaceuticals Research and Development Expense (Quarterly): 40.21M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 40.21M |
| December 31, 2023 | 37.35M |
| September 30, 2023 | 33.16M |
| June 30, 2023 | 32.18M |
| March 31, 2023 | 27.83M |
| December 31, 2022 | 26.02M |
| Date | Value |
|---|---|
| September 30, 2022 | 22.04M |
| June 30, 2022 | 22.56M |
| March 31, 2022 | 15.00M |
| December 31, 2021 | 11.19M |
| September 30, 2021 | 9.849M |
| June 30, 2021 | 9.914M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
9.849M
Minimum
Sep 2021
40.21M
Maximum
Mar 2024
23.94M
Average
24.29M
Median
Research and Development Expense (Quarterly) Benchmarks
| Revolution Medicines Inc | 118.02M |
| Zentalis Pharmaceuticals Inc | 49.58M |
| Perspective Therapeutics Inc | 7.452M |
| Electromed Inc | 0.167M |
| Xtant Medical Holdings Inc | 0.527M |